PMS39 COST-EFFECTIVENESS OF RITUXIMAB VERSUS ALTERNATIVE ANTI-TUMOR NECROSIS FACTOR (TNF) THERAPY AFTER PREVIOUS FAILURE OF ONE ANTI-TNF AGENT FOR TREATMENT OF RHEUMATOID ARTHRITIS IN COSTA RICA
Nov 1, 2010, 00:00
10.1016/S1098-3015(11)72192-1
https://www.valueinhealthjournal.com/article/S1098-3015(11)72192-1/fulltext
Title :
PMS39 COST-EFFECTIVENESS OF RITUXIMAB VERSUS ALTERNATIVE ANTI-TUMOR NECROSIS FACTOR (TNF) THERAPY AFTER PREVIOUS FAILURE OF ONE ANTI-TNF AGENT FOR TREATMENT OF RHEUMATOID ARTHRITIS IN COSTA RICA
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)72192-1&doi=10.1016/S1098-3015(11)72192-1
First page :
A309
Section Title :
RESEARCH POSTER ABSTRACTS
Open access? :
No
Section Order :
352